Ibrutinib in Relapsed Nodular Lymphocyte-predominant Hodgkin Lymphoma (NLPHL)
Status:
Completed
Trial end date:
2020-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to determine
1. Disease stabilization/response rate after six 21-day cycles of ibrutinib
2. Remission status after six, twelve and 20 21-day cycles of ibrutinib